Antigen-Peptide-Transporter 2 Deficiency Overview

Save information for later
Sign Up

Learn About Antigen-Peptide-Transporter 2 Deficiency

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Antigen-Peptide-Transporter 2 Deficiency Local Doctors?
Distinguished in Antigen-Peptide-Transporter 2 Deficiency
Endocrinology
Distinguished in Antigen-Peptide-Transporter 2 Deficiency
Endocrinology
200 1st St Sw, 
Rochester, MN 
Languages Spoken:
English

Michael Jensen is an Endocrinologist in Rochester, Minnesota. Dr. Jensen is rated as a Distinguished provider by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. His top areas of expertise are Antigen-Peptide-Transporter 2 Deficiency, Obesity, Heart Failure with Preserved Ejection Fraction (HFpEF), Gastric Bypass, and Endoscopy.

Distinguished in Antigen-Peptide-Transporter 2 Deficiency
Distinguished in Antigen-Peptide-Transporter 2 Deficiency
Montreal, QC, CA 

Sylvia Santosa practices in Montreal, Canada. Ms. Santosa is rated as a Distinguished expert by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. Her top areas of expertise are Antigen-Peptide-Transporter 2 Deficiency, Obesity, Isolated Hypogonadotropic Hypogonadism, and Obesity in Children.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Antigen-Peptide-Transporter 2 Deficiency
Distinguished in Antigen-Peptide-Transporter 2 Deficiency
Aydin, TR 

Gokhan Cesur practices in Aydin, Turkey. Cesur is rated as a Distinguished expert by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. Their top areas of expertise are Antigen-Peptide-Transporter 2 Deficiency, Methimazole Antenatal Exposure, Hypothyroidism, and Congenital Hypothyroidism.

What are the latest Antigen-Peptide-Transporter 2 Deficiency Clinical Trials?
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Summary: This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blin...

Match to trials
Find the right clinical trials for you in under a minute
Get started